Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 665: MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as single agent and combined with ruxolitinib

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMaria Luisa IannittoDBDiego BisignanoSZSonia Zicari

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Iannitto et al. (2024) studied this question.

synapsesocial.com/papers/68e72e37b6db6435876a7e4bhttps://doi.org/10.1158/1538-7445.am2024-665
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3628: Combined mek and jak inhibition <i>in vitro</i> is an effective strategy in overcoming jak inhibitor resistance in primary myelofibrosis (PMF)2024
  2. 2The Path Forward in MF: Small Molecules in the Limelight2026
  3. 3EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)2025 · 1 citations
  4. 4Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor2025
  5. 5Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms2025